Novavax COVID-19 Vaccine Nuvaxovid(TM) Recommended for Expande...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
GAITHERSBURG, Md., June 24, 2022 /PRNewswire-AsiaNet/ -- --Upon authorization, Nuvaxovid(TM) would be the first protein-based option for adolescents aged 12 through 17 in Europe--Nuvaxovid(TM) demonstrated 80% efficacy and was generally well-tolerated in adolescentsNovavax, Inc. (Nasdaq: NVAX), a ...
Authors: LATEST ASIANET NEWS RELEASES